Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Gyre Therapeutics (GYRE)  
$0.51 0.00 (0.00%) as of 4:30 Mon 10/30


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 31,350,000
Market Cap: 16.03(M)
Last Volume: 15,038 Avg Vol: 14,997
52 Week Range: $0.2246 - $0.648
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Catalyst Biosciences is a research and clinical development biopharmaceutical company. Co.'s complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, improved albumin-fused Complement Factor I (CFI) molecule intended for prophylactic subcutaneous or intravitreal administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential component 3 degrader product candidate in preclinical development for the treatment of dry age-related macular degeneration. Co. has several engineered protease programs in discovery or early non-clinical development.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 9,750
Total Buy Value $0 $0 $0 $4,584
Total People Bought 0 0 0 3
Total Buy Transactions 0 0 0 3
Total Shares Sold 60,000 60,000 60,000 60,000
Total Sell Value $950,777 $950,777 $950,777 $950,777
Total People Sold 1 1 1 1
Total Sell Transactions 3 3 3 3
End Date 2024-03-10 2023-12-08 2023-06-09 2022-06-09

   
Records found: 530
  Page 14 of 22  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Caldwell William S SVP - Drug Discovery and Dev.   •       –      –    2010-04-16 4 S $23.02 $850,371 D/D (36,946) 7,735     -
   Caldwell William S SVP - Drug Discovery and Dev.   •       –      –    2010-04-16 4 OE $5.10 $188,425 D/D 36,946 44,681     -
   Hicks Karen A VP Human ResourcesOfficer   •       –      –    2010-04-13 3 IO $0.00 $0 D/D 0 4,226     -
   Hodges Mauri K VP Finance & Corp SystemsOffic   •       –      –    2010-04-13 3 IO $0.00 $0 D/D 0 1,159     -
   Zorn Peter A SVP, Lg Affrs, GC and Secrtary   •       –      –    2010-03-31 4 S $19.41 $6,075 D/D (313) 0     -
   Zorn Peter A SVP, Lg Affrs, GC and Secrtary   •       –      –    2010-03-31 4 OE $5.10 $1,596 D/D 313 313     -
   Snyderman Ralph Director   –       •      –    2010-02-16 4 S $19.92 $298,821 D/D (15,000) 0     -
   Snyderman Ralph Director   –       •      –    2010-02-16 4 OE $7.10 $122,775 D/D 15,000 15,000     -
   Bencherif Merouane VP, Preclinical Research   •       –      –    2010-01-15 4 S $20.51 $1,499,452 D/D (73,108) 0     -
   Bencherif Merouane VP, Preclinical Research   •       –      –    2010-01-15 4 OE $1.75 $328,301 D/D 73,108 73,108     -
   Bencherif Merouane VP, Preclinical Research   •       –      –    2010-01-04 4 S $20.81 $160,946 D/D (7,735) 0     -
   Zorn Peter A VP, Lg Affrs, GC and Secrtary   •       –      –    2009-12-31 4 S $21.02 $92,663 D/D (4,404) 0     -
   Zorn Peter A VP, Lg Affrs, GC and Secrtary   •       –      –    2009-12-31 4 OE $5.10 $24,302 D/D 4,404 4,092     -
   Caldwell William S VP - Drug Discovery and Dev.   •       –      –    2009-12-16 4/A S $21.93 $508,977 D/D (23,206) 7,735     -
   Caldwell William S VP - Drug Discovery and Dev.   •       –      –    2009-12-16 4/A OE $3.53 $81,801 D/D 23,206 30,941     -
   Caldwell William S VP - Drug Discovery and Dev.   •       –      –    2009-12-16 4 S $21.93 $508,868 D/D (23,201) 7,735     -
   Caldwell William S VP - Drug Discovery and Dev.   •       –      –    2009-12-16 4 OE $3.53 $81,784 D/D 23,201 30,936     -
   Debethizy J Donald President and CEO   •       •      –    2009-12-16 4 S $21.98 $5,230,437 D/D (237,930) 0     -
   Debethizy J Donald President and CEO   •       •      –    2009-12-16 4 OE $1.75 $377,772 D/D 209,004 237,930     -
   Bencherif Merouane VP, Preclinical Research   •       –      –    2009-12-16 4 S $21.93 $340,663 D/D (15,532) 7,735     -
   Bencherif Merouane VP, Preclinical Research   •       –      –    2009-12-16 4 OE $8.51 $132,177 D/D 15,532 23,267     -
   Dunbar Geoffrey C VP, Clin. Dev. & Reg. Affairs   •       –      –    2009-12-16 4 S $21.86 $494,170 D/D (22,602) 1,153     -
   Musso Alan A VP, CFO & Treasurer   •       –      –    2009-12-16 4 S $22.27 $22,269 D/D (1,000) 2,799     -
   Musso Alan A VP, CFO & Treasurer   •       –      –    2009-12-16 4 OE $5.10 $5,100 D/D 1,000 3,799     -
   Musso Alan A VP, CFO & Treasurer   •       –      –    2009-12-15 4 S $22.31 $263,427 D/D (11,809) 2,799     -
  530 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 14 of 22
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us